

Scholars Research Library

Der Pharma Chemica, 2015, 7(10):112-127 (http://derpharmachemica.com/archive.html)



ISSN 0975-413X CODEN (USA): PCHHAX

The bioactive molecule resveratrol (RVTL) obtained from the black grapes (*Vitis vinefera*) act as potential hepatocytes regenerators and cytotoxic agent

Asish Bhaumik^{*1}, Shibu Das², Soma Acharjee², Prasenjit Das³, G. Mani¹ and J. Swarnalatha¹

¹Department of Pharmaceutical Chemistry, Teja College of Pharmacy, Kodad, Nalgonda, Telangana, India ²Department of Pharmaceutical Chemistry, Regional Institute of Pharmaceutical Science and Technology, Agartala, Tripura, India

³Department of Pharmacy, Tripura University, Suryamaninagar, Tripura(W), Agartala, Tripura, India

ABSTRACT

The main aim and objective of the present research work was the extraction, isolation and characterization of bioactive molecule resveratrol (RVTL) from the black grapes (Vitis vinefera) and in vivo evaluation of hepatocytes regenerator potentiality against CCl_4 induced rat hepatocytes and in vitro cytotoxic activity against both human colon cancer cell line HT-29 and human breast cancer HS 578T Cell line. Based on this a new series of constituents had been planned to extract by Ethanol (ENL) from black grapes. The isolation and characterization of bioactive molecule resveratrol (RVTL) were carried out from the ENL extract of the black grapes (Vitis vinefera) by modern analytical techniques such as U.V, I.R, ¹H-NMR and ¹³C-NMR, JEOL GCmate and HPLC-ESI-MS/MS spectroscopy. In-vivo hepatoprotective activity was carried out by using albino rats. The results displayed that the elevated levels of SGOT, SGPT, ALP and Serum bilirubin were mainly due to CCl₄ intoxication, reduced significantly (*P<0.05) in rats, after treatment with ENL extract containing RVTL of black grapes (Vitis vinefera). Treatment with ENL extract of black grapes (Vitis vinefera) at a both doses of 250 and 500 mg/kg b.w. significantly decreased the SGOT, SGPT, ALP, Serum Bilirubin levels by 23.5%, 28.9%, 8.9%, and 17.2% (at low dose) and 26.9%, 35.9%, 14.5% and 22.3% (at high dose) respectively. Silymarin used as standard drug showed a reduction of 56.09%, 69.89%, 57.46% and 19.04%^{ns} receiving CCl_4 alone. Histopathological investigation displayed that at both doses (250 mg/kg b.w. and 500 mg/kg b.w.), the ENL extract of black grapes (Vitis vinefera) was possessed very good hepatoprotective activity, but at 500 mg/kg b.w. executed excellent hepatoprotective activity against CCl4 induced damaged hepatocytes. The in vitro cytotoxic activity was carried out by SRB assay. The results obtained from the in-vitro studies performed by SRB assay using the HT-29 cell lines and HS 578T displayed that the ENL extract containing RVTL of black grapes (Vitis vinifera) possessed a very good cytotoxic activity. From the present studied it had been concluded that ENL extract containing RVTL of black grapes (Vitis vinifera) exhibiting the potential capability to kill the neoplastic cell when compared with standard drug 5-FU and doxorubicin. The ENL extract containing RVTL of black grapes (Vitis vinifera) displayed with the highest 93.43% growth inhibition at 12.5 μg ($IC_{50} = 2.2 \ \mu g/ml$) against human colon cancer cell line HT-29 and 93.6% growth inhibition at 25 μg ($IC_{50} = 1.9$ $\mu g/ml$) against human breast cancer HS 578T Cell line.

Key words: Hepatoprotective, HT-29, HS 578T, Bioactive molecule, SRB, IC50 etc.

INTRODUCTION

Resveratrol (3,5,4'-trihydroxy-*trans*-stilbene) is a stilbenoid, a type of natural phenol, and a phytoalexin produced naturally by several plants in response to injury or when the plant is under attack by pathogens such as bacteria or fungi [1]. Food sources of resveratrol include the skin of grapes, blueberries, raspberries, and mulberries [2]. As of 2014, there is limited evidence of health effects in humans.

Occurrences

Plants: Resveratrol was originally isolated by Takaoka from the roots of hellebore in 1940, and later, in 1963, from the roots of Japanese knotweed. It attracted wider attention only in 1992, however, when its presence in wine was suggested as the explanation for cardioprotective effects of wine [3].

In grapes, trans-resveratrol is a phytoalexin produced against the growth of fungal pathogens such as Botrytis cinerea [4]. Its presence in Vitis vinifera grapes can also be constitutive, with accumulation in ripe berries of different levels of bound and free resveratrols, according to the genotype [5]. In grapes, resveratrol is found primarily in the skin [6] and, in muscadine grapes, also in the seeds [7] The amount found in grape skins also varies with the grape cultivar, its geographic origin, and exposure to fungal infection. The amount of fermentation time a wine spends in contact with grape skins is an important determinant of its resveratrol content [6].

Foods: The levels of resveratrol found in food varies greatly. Red wine contains between 0.2 and 5.8 mg/l,[8] depending on the grape variety, while white wine has much less, because red wine is fermented with the skins, allowing the wine to extract the resveratrol, whereas white wine is fermented after the skin has been removed [6][9]. The composition of wine is different from that of grapes since the extraction of resveratrols from grapes depends on the duration of the skin contact, and the resveratrol 3-glucosides are in part hydrolysed, yielding both trans- and cisresveratrol [10]. A number of reports have indicated muscadine grapes may contain high concentrations of resveratrol, and that wines produced from these grapes, both red and white, may contain more than 40 mg/l, [7], [11] however, subsequent studies have found little or no resveratrol in different varieties of muscadine grapes [12], [13].

One of the most promising sources is peanuts, especially sprouted peanuts where the content rivals that in grapes. Before sprouting, it was in the range of 2.3 to $4.5\mu g/g$, and after sprouting, in the range of 11.7 to 25.7 $\mu g/g$ depending upon peanut cultivar [14]. The fruit of the mulberry (esp. the skin) [15] is a source, and is sold as a nutritional supplement.Cocoa powder, baking chocolate, and dark chocolate also have low levels of resveratrol in normal consumption quantities (0.35 to 1.85 mg/kg) [16].

Pharmacological activities

There are a number of promising animal studies and some data from human clinical trials is emerging [17],[18] Nevertheless, there is not enough evidence to recommend consumption of resveratrol beyond the amount that can be obtained through dietary sources, and more human clinical trials are needed [19].

Cancer: As of 2014, the results of limited human clinical trials with small samples sizes of the effects of resveratrol on cancer are inconsistent. Testing of resveratrol in animal models of cancer have also shown mixed results [20]. The strongest evidence of anticancer action of resveratrol exists for tumors it can contact directly, such as skin and gastrointestinal tract tumors. For other cancers, the evidence is uncertain, even if massive doses of resveratrol are used [21]. Resveratrol treatment appeared to prevent the development of mammary tumors in animal models; however, it had no effect on the growth of existing tumors. Paradoxically, treatment of prepubertal mice with high doses of resveratrol enhanced formation of tumors. Injected in high doses into mice, resveratrol slowed the growth of neuroblastomas [21].

Cardioprotective effects: Moderate drinking of red wine has long been known to reduce the risk of heart disease [22] This is best known as "the French paradox" [23], [24]. Studies suggest resveratrol in red wine may play an important role in this phenomenon [25]. It appears to stimulate endothelial nitric oxide synthase (eNOS) activity; [26] and inhibition of platelet aggregation [27]. The cardioprotective effects of resveratrol also are theorized to be a form of preconditioning the best method of cardioprotection, rather than direct therapy [28] Study into the cardioprotective effects of resveratrol is based on the research of Dipak K. Das. However, he has been found guilty of scientific fraud, and many of his publications related to resveratrol have been retracted [29] [30].

Antidiabetic effects: Other diabetic animal model studies by different researchers have also demonstrated the antidiabetic effects of resveratrol [31], [32] This compound was shown to act as agonist of PPARgamma, nuclear receptor that is current pharmacological target for the treatment of diabetes type 2 [33]

Skin protection: The oxidative stress induced by ultraviolet radiation is one of the main causes for premature skin ageing. The photoprotective effects of several polyphenols known for their antioxidant properties, including resveratrol, have been investigated in silico and in topical application conditions.[34], [35]

Neuroprotective effects: The neuroprotective effects have been confirmed in several animal model studies [36]

Sirtuin activation: Some of the benefits demonstrated in previous studies were overstated [37], [38] however, this study was challenged immediately, [39] and a few experiments were suggested to be of inferior quality [40].

Psychological: In a number of animal models resveratrol has had an antidepressant-like effect. Whether or not there is any effect in humans is unclear [41].

MATERIALS AND METHODS

Drug and chemicals

The standard drugs Silymarin (hepatoprotective agent), 5-flurouracil and Doxorubicin (anticancer drugs) purchased from Local Retail Pharmacy Shop and solvents and other chemicals were used for the extraction from Institutional Store and were of AR grade. In the present study the *in-vivo* hepatoprotective activity was evaluated by CCl_4 induced hepatotoxicity model in rats.

Instrumentation

The IR spectra were recorded in the solid state as a KBr dispersion medium using the FT-IR (Perkin Elmer, Spectrum 65 & JASCO-FT-IR-430) spectrophotometer. The UV spectrum was recorded on a Shimadzu UV-visible spectrophotometer using acetonitrile as the medium. The 1H NMR and 13C NMR experiments for resveratrol were performed at 400.13 MHz and 100.62 MHz, respectively, on the Bruker Avance 400 MHz FT NMR spectrometer with a multinuclear BBO probe. DMSO- d6 was used as the solvent. HPLC/MS/MS analyses were performed using a system consisting of a Finnigan autosampler a Finnigan LC pump, a Finnigan TSQ Quantum Ultra equipped with an electrospray ion source and operated by XCalibur software. HPLC–ESI–MS/MS and was adopted to analyze trans-resveratrol. The Mass spectra of trans-resveratrol also recorded by JEOL GCmate.

Experimental animals

White male albino rats weighing about 200-250 g were used. They were obtained from the animal house of C.L. Baid Metha College of Pharmacy, Chennai. They were kept under observation for about 7 days before the onset of the experiment to exclude any intercurrent infection, had free access to normal diet and water. The animals were housed in plastic well aerated cages at normal atmospheric temperature (25 ± 5 °C) and normal 12- hour light/dark cycle under hygienic conditions.

Cell cultures

The cell culture human colon cancer cell line **HT-29** and human breast cancer **HS 578T Cell line** were provided by National Centre for Cell Science (NCCS), Pune and were grown in Eagles Minimum Essential Medium (EMEM) which contained 10% fetal bovine serum (FBS). All cells were maintained at 37°C, 100% relative humidity, 5% CO2, 95% air and the culture medium was changed twice a week.

Methodology for extraction [42]

Weigh 20 g of black grapes paste (ripen can be mashed to prepare a paste) into a 250 ml round-bottomed flask. Add 50 ml of ethanol and 60 ml of dichloromethane. Heat the mixture under reflux for 5 min on stem-bath with frequent shaking. Filter the mixture under suction and transfer the filtrate to a separatory funnel. Wash this mixture containing bioactive compounds with three portions of 150 ml each with sodium chloride solution. Dry the organic layer over anhydrous magnesium sulfate. Filter and evaporate most of the solvent in vacuum without heating.

Preliminary Phytochemical screening [43, 44, 45]

Preliminary Phytochemical screening of ENL extract of black grapes (*Vitis vinifera*) had shown the presence of various bioactive compounds such as carbohydrates, aminoacids and peptides, phytosterols, carotenoids and polyphenols (higher concentration).



Fig 2a: IR spectra for Resveratrol





Fig 3b: NMR spectra for trans (A) and cis (B)-Resveratrol







Fig 4b: Mass spectra for Resveratrol (HPLC/MS/MS)

IR & UV Spectroscopy

The UV spectrum was recorded on a Shimadzu UV-visible spectrophotometer using acetonitrile as the medium. The IR spectrum displayed characteristic absorptions at, 3422 (broad signal), 3027, 2929, 1511, and 1492 cm–1 which is indicative of O-H, aromatic C-H, methylene C-H, and aromatic –C=C stretching functionality.

NMR spectroscopy

The 1H chemical shift values were reported on the δ scale in ppm, relative to TMS ($\delta = 0.0$ ppm) and in the ¹³C NMR, the chemical shift values were reported relative to DMSO-d6 ($\delta = 39.50$ ppm) as a reference. The DEPT-135 spectra revealed the presence of methyl and methine groups as positive peaks and methylene as negative peaks. 1H NMR data indicate the alkene hydrogens at the C7 and C8 positions observed as two doublets at δ 6.25–6.35 ppm with a coupling constant J1,3 =12.28 Hz which confirms the cis orientation of the two alkene hydrogens [14]. In trans-resveratrol, these two alkene hydrogens were observed at around δ 6.79–6.90 ppm with a coupling constant J1,3 = 16.2 Hz. The three hydroxyl groups were observed as broad signals at δ 9.19 (2H's) and 9.47 ppm, which disappear on D2O exchange studies. The aromatic hydrogen between the two hydroxyl substituents at the C4 position was found to be shielded to δ 6.05 ppm as a triplet with a meta coupling constant of J1,3 = 2.1 Hz, similar to that of trans-resveratrol. The hydrogens at the 2 and 6 positions were shielded to δ 6.11 and appear as doublets with a coupling constant J1,3 = 2.2 Hz, which is a characteristic coupling constant for the aromatic hydrogens in the meta position .The remaining aromatic hydrogens at 10, 11, 13, and 14 appear as two doublets δ 6.60 & 7.06 ppm with a coupling constant of J1,3 = 6.7 Hz, which matches the coupling constant for the ortho coupling in aromatic systems, and also the splitting pattern matches the p-substituted aromatic compounds.

In the 13C NMR spectrum, three carbons deshielded more than the others and were observed as two sets at δ 156.7 and 158.4 ppm, which indicate that these carbons are attached to hydroxyl groups and assigned for the C3, C5, and C12 carbons. Due to the hydroxyl substituent effect at the ortho position, the carbons at C4, C6, C2, C11, and C13 appear more shielded at δ 101.6 (1C), 106.4 (2C), and 115.0 (2C) ppm. By using DEPT NMR data, all of the carbon signals were assigned. The NMR spectral data matches that reported for cis-resveratrol.

In dimethyl sulfoxide (DMSO), the 1 H-NMR data were as follows: 6.11 (m, 1H, H-4), 6.37 (d, 2H, J¹/₄2.0 Hz, H-2, H-6), 6.76 (d, 2H, J¹/₄8.5 Hz, H-3 0, H-5 0), 6.90 (d, 1H, J¹/₄16.3 Hz, H-a), 6.92 (d, 1H, J¹/₄16.3 Hz, H b), 7.39 (d, 2H, J¹/₄8.5 Hz, H-2 0, H-6 0), 9.17 (s, 2H, 3-OH, 5-OH), 9.52 (s,1H, 4 0 -OH). From the above data, it was easy to confirm resveratrol.

Mass spectroscopy

HPLC/MS/MS analyses were performed using a system consisting of a Finnigan autosampler, a Finnigan LC pump, a Finnigan TSQ Quantum Ultra equipped with an electrospray ion source and operated by XCalibur software. HPLC–ESI–MS/MS and was adopted to analyze trans-resveratrol. The Mass spectra of trans-resveratrol also recorded by JEOL GCmate. The data were shown here: parent ion [M-H]⁻ m/z 227, main product ions m/z 185, 143, 117 and 119. The molecular mass of trans-resveratrol is 228.

Structure of Resveratrol



5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol



5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol

Evaluation of acute toxicity [46]

In the present study the acute oral toxicity of the ethanolic extract (ENL) of black grapes (*Vitis vinifera*) was performed by acute toxic class method. In this method the toxicity of the extract was planned to test using step wise procedure, each step using three Wister rats. The rats were fasted prior to dosing (food but not water should be withheld) for three to four hrs. Following the period of fasting the animals were weighed and the extract was administered orally at a dose of 2000 mg/Kg b.w. Animals were observed individually after dosing at least once

during the first 30 min; periodically the surveillance was carried out for the first 24 hrs with special attention given during the first 4 hrs and daily thereafter, for a total of 14 days.

Experimental protocol for Hepatoprotetive activity [47]

A total of 30 rats were taken and divided into 5 groups of 6 rats each

(A) Group I: Normal Control Group [NCG - (only the vehicle (1 mL/kg/day of 1% CMC; p.o.)].

(B) Group II: Negative Control Group [Neg.CG – (CCl4 1 mL/kg (1:1 of CCl₄ in olive oil) i.p].

(C) Group III: Positive Control/Standard Group [SG - CCl_4 1 mL/kg (1:1 of CCl_4 in olive oil) i.p.+ Standard Silymarin 100 mg/kg orally (p.o.) for 7 days]

Treatment Groups

(**D**) **Group IV:** High Dose Group [**HDG** - CCl₄ 1 mL/kg (1:1 of CCl₄ in olive oil) i.p + ENL extract of BG (**Black** grapes) (500 mg/ kg b. w., p.o.)]

(E) Group V: Low Dose Group [LDG - CCl_4 1 mL/kg (1:1 of CCl_4 in olive oil) i.p + ENL extract of BG (250 mg/ kg b. w., p.o.)]. Treatment was given daily for seven days orally.

Collection of blood: On the 8th day, blood was collected by retro orbital puncture, under mild ether anesthesia after 8 hr fasting. Blood samples were centrifuged at 3000 rpm for 20 mins. Serum was separated and stored at -200^{0} C until biochemical estimations.

Biochemical Analysis

The Serum samples were analyzed for

- (I) Alanine Aminotransferase (ALT) (SGPT)
- (II) Aspartate Aminotransferase (AST) (SGOT)
- (III) Alkaline Phosphatase (ALP)

(IV) Serum Bilirubin

Histopathological Analysis

The liver tissue was dissected out and fixed in 10% formalin solution. It was then dehydrated in ethanol (50%-100%), cleared in xylene and embedded in paraffin wax. Afterwards thick sections (5-6 mm) were made and then stained with hematoxylin and eosin dye for photo microscopic observation. The whole biochemical and histopathological analysis was carried out at V.H.S Hospital in Chennai.

Evaluation of in vitro Cytotoxic activity by SRB Assay

Principle [48, 49]

Sulphorodamine B (SRB) is a bright pink aminoxanthine dye with two sulfonic acid group. Under mild acidic conditions SRB dye binds to basic amino acid residues in trichloro acetic acid (TCA) fixed cells to provide a sensitive index of cellular protein content that is linear over a cell density range of visible at least two order of magnitude.

Procedure [50]

The monolayer cell culture was trypsinized and the cell count was adjusted to 0.5-1.0x105 cells/ml using medium containing 10% new born sheep serum. To each well of the 96 well microtitre plate, 0.1 ml of the diluted cell suspension (approximately) 10,000 cells was added. After 24 hrs, when a partial monolayer was formed, the supernatant was flicked off, washed once and **100 µl**, **50µl and 25µl and 12.5µl (in case of HT 29 Cell line) and 150µl, 100µl, 50 µl and 25 µl (in case of HS 578T Cell line)** of different concentration of extracts of fruits of Vitis vinifera were added to the cell in microtitre plate. The plates were incubated at 370c for 72 hrs in 5% CO2 incubator, microscopic examination was carried out and observations were recorded every 24 hrs. After 72 hrs, 25µl of 50% TCA was added to wells gently such that it forms a thin layer over the test extracts to form overall concentrations 10%. The plates were incubated at 40c for 1 hr. The plates were flicked and washed five times with tap water to remove traces of medium sample and serum and were then air dried. The air dried plates were stained with 100 µl SRB and kept for 30 mnts at room temperature. The unbound dye was removed by rapidly washing four times with 1% acetic acid. The plates were then air dried. 100 µl of 10 mM Tris base was then added to the wells to solubilise the dye. The plates were shaken vigorousely for 5 mnts. The absorbance was measured using microplate reader at a 540 nm. The % growth inhibition was calculated by the following formula:

% cell growth inhibition = 100 - {(At - Ab / Ac - Ab)} x 100

At = Absorbance value of test compound. Ab = Absorbance value of blank.

Ac = Absorbance value of control.

RESULTS AND DISCUSSION

Group	Treatment	AST(SGOT) IU/L	ALT(SGPT) IU/L	ALP(SALP) IU/L	Sr. bilirubin mg/dL
1.	NCG	52.53±1.065	48.63±1.162	51.97±2.313	0.7267±0.1443
2.	Neg. CG	201.9±1.598***	209.5±2.858***	392.2±3.208***	7.300±1.012***
3.	LDG	187.9±1.489***	160.5±12.31***	358.7±2.028***	$4.633 \pm 0.2603^{***}$
4.	HDG	152.4±1.811***	122.5±13.84***	303.0±2.082***	3.397±0.3531*
5.	SG	91.60±1.795***	109.8±6.818***	155.7±6.240***	0.9000±0.0577 ^{ns}

Table: 1 for the assessment of Biochemical parameters











Fig: 4



Fig 5: Histopathological Examination of Hepatocytes treated with ethanolic extract Black grapes containing RVTL (BIOSPY)

Phytochemical screening

Preliminary Phytochemical screening of ENL extract of black grapes (*Vitis vinifera*) had shown the presence of various bioactive compounds such as carbohydrates, aminoacids and peptides, phytosterols, carotenoids and polyphenols (higher concentration) etc.

Acute Oral Toxicity Studies

In this study the acute oral toxicity was evaluated by "Acute toxic class methods (OECD guideline-423)". The extract was administered orally at a dose of 2000 mg/Kg b. wt. During the surveillance period no significant toxicity occurred along with minute non-considerable behavioral changes. After a statistical analysis by trial and error, the significant doses were chosen at 250 mg/kg b. wt p. o (LD) and 500 mg/kg b. wt p. o. (HD) considerably.

Hepatoprotective activity

Statistical analysis

The data were expressed as mean \pm SD. Statistical differences at *P < 0.05 between the groups were analyzed by one-way ANOVA followed by Dunnett's Multiple Comparison Test using Graph Pad Prism 5.04 Instate software package. The data's were compared with group 2 i.e. Negative Control group.

Biochemical analysis

The effects of ENL extract of Black grapes (Vitis vinefera) on liver marker enzymes and serum bilirubin content are displayed in **Table 1.** The data exhibited that Normal Control Group demonstrated a normal range of AST, ALT, and bilirubin levels while the CCl₄-treated group showed elevated levels of AST, ALT, and bilirubin, thus confirming that CCl₄ causes hepatocellular degeneration at higher doses. The elevation of cytoplasmic AST and ALT is considered an indicator for the release of enzymes from disrupted liver cells. Bilirubin concentration has been used to evaluate chemically induced hepatic injury. The Results displayed in Table 1 and Fig: 1, 2, 3 and 4 were indicated that the elevated levels of SGOT, SGPT, ALP and Serum bilirubin due to CCl₄ intoxication were reduced significantly (*P<0.05) in rats, after treatment with ENL extract of Black grapes (Vitis vinefera). Treatment with ENL extract of black grapes (Vitis vinefera) at a both doses of 250 and 500 mg/kg b.w. significantly decreased the SGOT, SGPT, ALP, Serum Bilirubin levels by 23.5%, 28.9%, 8.9%, and 17.2% (at low dose) and 26.9%, 35.9%, 14.5% and 22.3% (at high dose) respectively. Silymarin used as standard drug showed a reduction of 56.09%, 69.89%, 57.46% and 19.04%^{ns} receiving CCl₄ alone. So depending upon the data of Table 1 it was confirmed that the biochemical parameters of the group treated with ENL extract of Black grapes (Vitis vinefera) was significantly lower than the CCl₄-treated group. Moreover the treatment with the ENL extract of Black grapes (Vitis vinefera) significantly reduced the previously raised levels of AST, ALT, ALP and bilirubin in hepatotoxic rats.

Histopathological Analysis

The results of light microscopy examination of the transverse section of control, CCl_4 -treated and treated with ENL extract of Black grapes (*Vitis vinefera*) rat livers were represented in Fig 5. It was revealed that the liver section of animals treated with CCl_4 showed a high degree of damage characterized by cell vacuolation, pyknotic and degenerated nuclei and wall of bile capillaries. The normal architecture of the liver was lost. The intralobular vein was badly damaged with wide spaces at some sinusoids. Liver sections of these rats indicated necrosis, ballooning and degeneration in hepatic plates and loss of cellular boundaries. There was also a heavy accumulation of neutrophils surrounding the portal vein. These neutrophils act as an indicator of the occurrence of cell damage as they are absent in normal healthy tissues. The hepatocytes are disrupted and sinusoids are damaged as well.

Screening of cytotoxic activity

The results for cell growth inhibition by the ENL extract containing **RVTL** of black grapes (*Vitis vinifera*) against **HT29 cell lines and HS 578T Cell line** at various concentrations was shown in table 1, 2. As the concentration increases there is an increase in the cell growth inhibition and it was found that the highest 93.43% growth inhibition at 12.5 μ g (**IC**₅₀ = 2.2 μ g/ml) against human colon cancer cell line HT-29 and 93.6% growth inhibition at 25 μ g (**IC**₅₀ = 1.9 μ g/ml) against human breast cancer HS 578T Cell line. In the USNCI screening program a sample is generally considered to have *in vitro* antineoplastic activity, if the **IC**₅₀ value following incubation between 48 hrs and 72 hrs is <4 μ g/ml or 10 μ M. In the present study IC₅₀ value of standard drug 5-FU and doxorubicin were found to be 1.91 μ g/ml with 96.54 % growth inhibition at 1.5 μ g/ml and 1.81 μ g/ml with 96.64% growth inhibition at 2.5 μ g/ml respectively. Flavanoid and carotenoid compounds possessed the highest anticancer activity obtained from the natural sources.

IC₅₀ Determination [51]

 IC_{50} is the acronym for "half maximal inhibitory concentration". IC_{50} value indicates the concentration needed to inhibit a biological or biochemical function by half (e.g. inhibition of enzymes, affinity to cell receptors). IC_{50} is calculated by the following formula:

 $IC_{50} = (50\% - Low Inh\%) / (High Inh\% - Low Inh\%) x (HighConc-Low Conc) + Low Conc. Low Inh\% / High Inh\% : % inhibition directly below / above 50% inhibition$

Low Conc / High Conc : Corresponding concentrations of test compound.

 Table 2: For percentage (%) of Cell Growth Inhibition by Ethanolic Extract (ENL) of Fruits of Vitis vinifera containing RVTL on HT-29

 Cell lines by SRB Assay

Serial no.	Concentration of the Extracts	Absorbance of extracts	Inhibition of cell growth (%)
1	12.5 µg/ml	0.019	93.43
2	25 μg/ml	0.022	92.3
3	50 μg/ml	0.027	90.6
4	100 µg/ml	0.033	88.59
5	1.5 μg/ml (5-FU)	0.010	96.54
6	Control	0.289	0



Fig 6: Percentage (%) of cell Growth Inhibition by ENL extract of black grapes (*Vitis vinifera*) containing RVTL on Human Colon Cancer HT-29 Cell line



Fig 7: Graphical representation of Percentage (%) of cell Growth Inhibition by ENL extract of Black grapes (*Vitis vinifera*) on HT-29 Cell line at different concentration

 Table 3: For percentage (%) of cell Growth Inhibition by Ethanolic Extract (ENL) of Fruits of Vitis vinifera containing RVTL on HS-578T Cell line by SRB Assay

Serial no.	Concentration of the Extracts	Absorbance of extracts	Inhibition of cell growth (%)
1	25 μg/ml	0.019	93.6
2	50 μg/ml	0.025	91.58
3	100 µg/ml	0.034	88.56
4	150 μg/ml	0.039	86.87
5	2.5 μg/ml (Doxorubicin)	0.010	96.64
6	Control	0.297	0



Fig 8: Percentage (%) of cell Growth Inhibition by ENL extract of black grapes (*Vitis vinifera*) containing RVTL on Human breast Cancer HS-578T Cell line



Fig 9: Graphical representation of Percentage (%) of cell Growth Inhibition by ENL extract of Black grapes (*Vitis vinifera*) on HS-578T Cell line at different concentration

CONCLUSION

In conclusion, we report here that the **ENL extract containing RVTL** of black grapes (*Vitis vinifera*) had ability to regenerate the hepatocytes *in vivo* and also possessed potential antiinflmmatory activity which was confirmed by liver biopsy. The hepatoprotective activity of the ENL extract of Black grapes (*Vitis vinefera*) could be considered as excellent with regards to the standard drug silymarin.

The results obtained from the *in-vitro* studies performed by SRB assay using the **HT-29 cell lines and HS 578T** displayed that the **ENL extract containing RVTL of black grapes** (*Vitis vinifera*) possessed a very good antineoplastic activity. From the present studied it had been concluded that **ENL extract containing RVTL of black grapes** (*Vitis vinifera*) exhibiting the potential capability to kill the neoplastic cell when compared with standard drug **5-FU and doxorubicin**. The **ENL extract containing RVTL of black grapes** (*Vitis vinifera*) displayed with the highest 93.43% growth inhibition at 12.5 μ g (IC₅₀ = 2.2 μ g/ml) against human colon cancer cell line HT-29 and 93.6% growth inhibition at 25 μ g (IC₅₀ = 1.9 μ g/ml) against human breast cancer HS 578T Cell line.

REFERENCES

[1] Fremont, Lucie. *Life Sciences* 66: 663–673. doi:10.1016/S0024-3205(99)00410-5. Retrieved 6 June 2014.
[2] Jasiński M, Jasińska L, Ogrodowczyk M; Jasińska; Ogrodowczyk (August 2013). *Cent European J Urol* 66 (2): 144–9. doi:10.5173/ceju.2013.02.art8 (inactive 2015-02-01). PMC 3936154. PMID 24579014.
[3] Baur JA, Sinclair DA; Sinclair (June 2006). *Nature Reviews Drug Discovery* 5 (6): 493–506. doi:10.1038/nrd2060. PMID 16732220.

[4] Favaron, F.; Lucchetta, M.; Odorizzi, S.; Pais da Cunha, A.T.; Sella, L. (**2009**). *Journal of Plant Pathology* 91 (3): 579–88. doi:10.4454/jpp.v91i3.549 (inactive **2015**-02-01).

[5] Gatto P, Vrhovsek U, Muth J, Segala C, Romualdi C, Fontana P, Pruefer D, Stefanini M, Moser C, Mattivi F, Velasco R; Vrhovsek; Muth; Segala; Romualdi; Fontana; Pruefer; Stefanini; Moser; Mattivi; Velasco (December 2008). *Journal of Agricultural and Food Chemistry* 56 (24): 11773–85. doi:10.1021/jf8017707. PMID 19032022.
[6] Roy, H., Lundy, S., Resveratrol, Pennington Nutrition Series, 2005 No. 7

[7] LeBlanc, Mark Rene (13 December 2005). "Cultivar, Juice Extraction, Ultra Violet Irradiation and Storage Influence the Stilbene Content of Muscadine Grapes (Vitis Rotundifolia Michx.)". Retrieved **2007**-08-15.

[8] Gu X, Creasy L, Kester A, Zeece M; Creasy; Kester; Zeece (August **1999**). *Journal of Agricultural and Food Chemistry* 47 (8): 3223–7. doi:10.1021/jf981211e. PMID 10552635.

[9] Mattivi F (June 1993). Z Lebensm Unters Forsch 196 (6): 522–5. doi:10.1007/BF01201331. PMID 8328217.

[10] Mattivi F, Reniero F, Korhammer S; Reniero; Korhammer (**1995**). *Journal of Agricultural and Food Chemistry* 43 (7): 1820–3. doi:10.1021/jf00055a013.

[11] Ector BJ, Magee JB, Hegwood CP, Coign MJ (**1996**). *American Journal of Enology and Viticulture* 47 (1): 57–62.

[12] Pastrana-Bonilla E, Akoh CC, Sellappan S, Krewer G; Akoh; Sellappan; Krewer (August **2003**). *Journal of Agricultural and Food Chemistry* 51 (18): 5497–503. doi:10.1021/jf030113c. PMID 12926904.

[13] Hudson TS, Hartle DK, Hursting SD, Nunez NP, Wang TT, Young HA, Arany P, Green JE; Hartle; Hursting; Nunez; Wang; Young; Arany; Green (September **2007**). *Cancer Res.* 67 (17): 8396–405. doi:10.1158/0008-5472.CAN-06-4069. PMID 17804756. MSKE [muscadine grape skin extract] does not contain significant quantities of resveratrol and differs from MSEE. To determine whether MSKE contains significant levels of resveratrol and to compare the chemical content of MSKE (skin) with MSEE (seed), HPLC analyses were done. As depicted in Supplementary Fig. S1A and B, MSKE does not contain significant amounts of resveratrol (<1 ?g/g by limit of detection).

[14] Wang KH, Lai YH, Chang JC, Ko TF, Shyu SL, Chiou RY; Lai; Chang; Ko; Shyu; Chiou (January **2005**). *Journal of Agricultural and Food Chemistry* 53 (2): 242–6. doi:10.1021/jf048804b. PMID 15656656.

[15] Stewart JR, Artime MC, O'Brian CA; Artime; O'Brian (July 2003). J. Nutr. 133 (7 Suppl): 2440S–2443S. PMID 12840221.

[16] Hurst WJ, Glinski JA, Miller KB, Apgar J, Davey MH, Stuart DA; Glinski; Miller; Apgar; Davey; Stuart (September **2008**). *Journal of Agricultural and Food Chemistry* 56 (18): 8374–8. doi:10.1021/jf801297w. PMID 18759443.

[17] Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S; Sahni; Ali; Sharma; Baboota (**2014**). *Expert Opinion on Drug Delivery* 11 (8): 1285–1298. doi:10.1517/17425247.2014.919253. ISSN 1742-5247. PMID 24830814.

[18] Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MT, Espín JC; Larrosa; González-Sarrías; Tomás-Barberán; García-Conesa; Espín (**2013**). *Curr. Pharm. Des.* 19 (34): 6064–93. doi:10.2174/13816128113199990407. PMC 3782695. PMID 23448440.

[19] Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A et al. (**2011**). *PLoS ONE* 6 (6): e19881. doi:10.1371/journal.pone.0019881. PMC 3116821. PMID 21698226

[20] Carter LG, D'Orazio JA, Pearson KJ; d'Orazio; Pearson (June **2014**). *Endocr. Relat. Cancer* **21** (3): R209–25. doi:10.1530/ERC-13-0171. PMC 4013237. PMID 24500760.

[21] Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL; Back; Tang; Kim; Kopelovich; Bickers; Kim (November **2007**). *Toxicol. Appl. Pharmacol.* 224 (3): 274–83. doi:10.1016/j.taap.**2006**.12.025. PMC 2083123. PMID 17306316.

[22] Szmitko PE, Verma S; Verma (January **2005**). *Circulation* 111 (2): e10–1. doi:10.1161/01.CIR.0000151608.29217.62. PMID 15657377.

[23] Ferrières J (January **2004**). *Heart* 90 (1): 107–11. doi:10.1136/heart.90.1.107. PMC 1768013. PMID 14676260. [24] Simini B (January **2000**). *Lancet* 355 (9197): 48. doi:10.1016/S0140-6736(05)71990-5. PMID 10615898.

[25] Kopp P (June **1998**). *Eur. J. Endocrinol.* 138 (6): 619–20. doi:10.1530/eje.0.1380619. PMID 9678525.

[26] Duffy SJ, Vita JA; Vita (**2003**). *Current Opinion in Lipidology* 14 (1): 21–7. doi:10.1097/01.mol.0000052857.26236.f2 (inactive 2015-02-01). PMID 12544657.

[27] Olas B, Wachowicz B; Wachowicz (August **2005**). *Platelets* 16 (5): 251–60. doi:10.1080/09537100400020591. PMID 16011975.

[28] Das DK, Maulik N; Maulik (February 2006). Mol. Interv. 6 (1): 36–47. doi:10.1124/mi.6.1.7. PMID 16507749.

[29] Weir, William; Megan, Kathleen (January 11, **2012**). "Investigation Finds UConn Professor Fabricated Research - Work Focused On Resveratrol, Chemical In Red Wine". Hartford Courant. Retraction Watch.

[30] Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J; Argmann; Gerhart-Hines; Meziane; Lerin; Daussin; Messadeq; Milne; Lambert; Elliott; Geny; Laakso; Puigserver; Auwerx (December **2006**). *Cell* 127 (6): 1109–22. doi:10.1016/j.cell.2006.11.013. PMID 17112576.

[31] Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA; Pearson; Price; Jamieson; Lerin; Kalra; Prabhu; Allard; Lopez-Lluch; Lewis; Pistell; Poosala; Becker; Boss; Gwinn; Wang; Ramaswamy; Fishbein; Spencer; Lakatta; Le Couteur; Shaw; Navas; Puigserver; Ingram; De Cabo; Sinclair (November **2006**). *Nature* 444 (7117): 337–42. Bibcode:2006Natur.444..337B. doi:10.1038/nature05354. PMID 17086191.

[32] Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG; Waltenberger; Pferschy-Wenzig; Blunder; Liu; Malainer; Blazevic; Schwaiger; Rollinger; Heiss; Schuster; Kopp; Bauer; Stuppner; Dirsch; Atanasov (**2014**). *Biochem Pharmacol* 92 (1): 73–89. doi:10.1016/j.bcp.2014.07.018. PMC 4212005. PMID 25083916.

[33] Afaq F, Mukhtar H; Mukhtar (**2006**). *Experimental Dermatology* 15 (9): 678–84. doi:10.1111/j.1600-0625.2006.00466.x. PMID 16881964.

[34] Baliga MS, Katiyar SK; Katiyar (**2006**). *Photochemical & Photobiological Sciences* 5 (2): 243–53. doi:10.1039/b505311k. PMID 16465310.

[35] Anekonda TS (September **2006**). *Brain Res Rev* 52 (2): 316–26. doi:10.1016/j.brainresrev.2006.04.004. PMID 16766037.

[36] "Longevity gene' may be dead end: study". The Raw Story. Agence France-Presse. September 12, 2011.

[37] Ledford H (September 2011). Nature. doi:10.1038/news.2011.549.

[38] Viswanathan M, Guarente L; Guarente (September **2011**). *Nature* 477 (7365): E1–2. Bibcode:2011Natur.477E...1V. doi:10.1038/nature10440. PMID 21938026.

[39] Lombard DB, Pletcher SD, Cantó C, Auwerx J; Pletcher; Cantó; Auwerx (September 2011). *Nature* 477 (7365): 410–1. Bibcode: **2011** *Natur*.477..410L. doi:10.1038/477410a. PMID 21938058.

[40] Pathak L, Agrawal Y, Dhir A; Agrawal; Dhir (Jul **2013**). *Expert Opinion on Investigational Drugs* 22 (7): 863–80. doi:10.1517/13543784.2013.794783. PMID 23642183.

[41] Raj.K. Bansal ,Laboratory manual of organic chemistry , 5th revised edition , PP- 238-239.

[42] P.C Dandiya, P.K.Sharma, Bio-chemistry and clinical pathology, second edition, PP- 17-18, 24, 47-48.

[43] Dr. G. Devala Rao, A Manual of Practical Biochemistry, pp 17.

[44] Jaswant Kaur, PV Chemistry of Natural Products, 2010 edition, PP-113-114, 116, 344-346, 381.

[45] "OECD guidelines – 423" for testing of chemicals, 2001, pp 1-14

[46] Garrat DC. The Quantitative Analysis of Drugs, Japan, Chapman and Hall, 1964, 456.

[47] Skehan P, Storeng R, Scudiero D, Monks A, McMahan J Vistica D et al. Evaluation of colorimetric protein and Biomass stains for analyzing Drug Effects upon Human Tumour Cell lines. Proceedings of the American Association for Cancer Research, **1989**; 30:612.

[48] Skehan P, Storeng R, Scudiero D, Monks A, McMahan J Vistica D et al. *Journal National Cancer Institute*, **1990**; 82 (13), 1107-1112.

[49] Master RW. Animal Cell Culture, cytotoxicity and viability assay, 3rd ed. 2000, p. 202-203.

[50] Pharmacelsus Contract Research Organization.